undamentalytics Newsletter
Sign in

Alector, Inc. income statement

In fiscal 2025, Alector, Inc. reported revenue of $21.0m, down 79.1% on the year before, operating income of −$156m (a -741.3% margin) and net income of −$143m, or −$1.39 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue4282121207134971012114
Research and development307310115718921019218612399
General and administrative7123559556157605441
Operating income−33−57−114−195−37−138−152−145−156−126
Income before tax—————−130−125−119−143−118
Income tax——00035000
Net income−32−52−105−190−36−133−130−119−143−118
Diluted EPS−$3.55−$4.62−$1.71−$2.45−$0.45−$1.62−$1.56−$1.23−$1.39−$1.09
Diluted shares (average)9m11m62m78m80m82m84m97m103m109m
EBITDA−32−56−111−189−31−132−146−140−150−122

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ALEC vs LCTXALEC vs KROSALEC vs SRZN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Alector, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Alector, Inc.